M. Berre

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

M. Makuuchi, V. Mazzaferro, M. Kudo, 2015, The Lancet. Oncology.

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

T. Tammela, A. Snapir, O. Petrenciuc, 2020 .

STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)

M. Makuuchi, V. Mazzaferro, M. Kudo, 2014 .

Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).

T. Tammela, A. Snapir, T. Sarapohja, 2019, Journal of Clinical Oncology.

Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples

T. Baère, P. Dessen, V. Lazar, 2014, Investigational New Drugs.